CA3070446A1 - Treating cancer by blocking the interaction of tim-3 and its ligand - Google Patents
Treating cancer by blocking the interaction of tim-3 and its ligand Download PDFInfo
- Publication number
- CA3070446A1 CA3070446A1 CA3070446A CA3070446A CA3070446A1 CA 3070446 A1 CA3070446 A1 CA 3070446A1 CA 3070446 A CA3070446 A CA 3070446A CA 3070446 A CA3070446 A CA 3070446A CA 3070446 A1 CA3070446 A1 CA 3070446A1
- Authority
- CA
- Canada
- Prior art keywords
- gal3
- tim
- cells
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536886P | 2017-07-25 | 2017-07-25 | |
| US62/536,886 | 2017-07-25 | ||
| PCT/US2018/043513 WO2019023247A1 (en) | 2017-07-25 | 2018-07-24 | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3070446A1 true CA3070446A1 (en) | 2019-01-31 |
Family
ID=65040896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3070446A Pending CA3070446A1 (en) | 2017-07-25 | 2018-07-24 | Treating cancer by blocking the interaction of tim-3 and its ligand |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12227567B2 (enExample) |
| EP (1) | EP3658172A4 (enExample) |
| JP (2) | JP7368856B2 (enExample) |
| CN (1) | CN111201030B (enExample) |
| AU (1) | AU2018308088B2 (enExample) |
| CA (1) | CA3070446A1 (enExample) |
| WO (1) | WO2019023247A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| EP3746123A4 (en) * | 2018-02-01 | 2021-12-01 | Memorial Sloan-Kettering Cancer Center | ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP7835441B2 (ja) * | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 |
| IL294486A (en) * | 2020-01-13 | 2022-09-01 | Truebinding Inc | Antibodies against gal3 and methods of use |
| JP7421400B2 (ja) * | 2020-03-30 | 2024-01-24 | アークレイ株式会社 | ヒトガレクチン－３の分析、検出、測定に関する抗体、方法及びキット |
| CN116157151A (zh) * | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| JP7825633B2 (ja) * | 2020-12-08 | 2026-03-06 | メモリアル スローン ケタリング キャンサー センター | ガレクチン－３に対する抗体及びその使用方法 |
| JP2024516616A (ja) | 2021-04-23 | 2024-04-16 | スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． | Ｔｉｍ－３を標的とする抗体及びその使用 |
| EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| JP2024526764A (ja) | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| AU2022388722A1 (en) | 2021-11-09 | 2024-05-23 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
Family Cites Families (764)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| JPH01207920A (ja) | 1988-02-16 | 1989-08-21 | Oki Electric Ind Co Ltd | ＩｎＰ半導体薄膜の製造方法 |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| IE911869A1 (en) | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
| WO1993006116A1 (en) | 1991-09-20 | 1993-04-01 | Syntex-Synergen Neuroscience Joint Venture | Glial derived neurotrophic factor |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US5624807A (en) | 1992-07-22 | 1997-04-29 | The Mclean Hospital Corporation | Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| DE69429925T2 (de) | 1993-10-20 | 2002-10-02 | Duke University, Durham | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID |
| US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| AU1287495A (en) | 1994-08-26 | 1996-03-22 | Human Genome Sciences, Inc. | Gabaa receptor epsilon subunit |
| HUT77081A (hu) | 1994-10-28 | 1998-03-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kináz NPK-110 |
| US6835555B1 (en) | 1994-11-01 | 2004-12-28 | Human Genome Sciences, Inc. | Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5650313A (en) | 1995-06-05 | 1997-07-22 | Human Genome Sciences, Inc. | Ubiquitin conjugating enzymes 8 and 9 |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US6576607B1 (en) | 1995-04-19 | 2003-06-10 | Acorda Therapeutics | Methods using CNS neurite outgrowth modulators |
| US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
| US6221645B1 (en) | 1995-06-07 | 2001-04-24 | Elan Pharmaceuticals, Inc. | β-secretase antibody |
| EP1637600A1 (en) | 1995-07-07 | 2006-03-22 | Darwin Molecular Corporation | Chromosome 1 gene and gene products related to Alzheimer's disease |
| US6156311A (en) | 1995-07-27 | 2000-12-05 | The American National Red Cross | Modulators of expression and function of LRP in alzheimer's disease |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| FR2741892B1 (fr) | 1995-12-04 | 1998-02-13 | Pasteur Merieux Serums Vacc | Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus |
| US5936078A (en) | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| AUPN896596A0 (en) | 1996-03-27 | 1996-04-26 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic molecules |
| AU719038B2 (en) | 1996-03-29 | 2000-05-04 | Trustees Of Boston University | Methods for diagnosing and treating Alzheimer's disease |
| US6455277B1 (en) | 1996-04-22 | 2002-09-24 | Amgen Inc. | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
| US5663059A (en) | 1996-05-10 | 1997-09-02 | Incyte Pharmaceuticals, Inc. | Human phospholipase inhibitor |
| US6010878A (en) | 1996-05-20 | 2000-01-04 | Smithkline Beecham Corporation | Interleukin-1 β converting enzyme like apoptotic protease-6 |
| CA2183901A1 (en) | 1996-08-22 | 1998-02-23 | Johanna E. Bergmann | Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans |
| DK0966533T3 (da) | 1997-02-07 | 2010-01-04 | Us Gov Health & Human Serv | Aktivitetsafhængig neurotrof faktor III (ADNF III). |
| US6413940B1 (en) | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| US6087153A (en) | 1997-07-24 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Sel-10 and uses thereof |
| IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
| US7384910B2 (en) | 1997-10-08 | 2008-06-10 | Castillo Gerardo M | Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| US6242421B1 (en) | 1997-11-06 | 2001-06-05 | Richard Lloyd Bowen | Methods for preventing and treating Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7189703B2 (en) | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| GB9816575D0 (en) | 1998-07-31 | 1998-09-30 | Zeneca Ltd | Novel compounds |
| US20050032675A1 (en) | 1998-08-06 | 2005-02-10 | Teijin Limited | Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| DE69931791T2 (de) | 1998-08-06 | 2007-05-24 | Teijin Ltd. | Pharmazeutische zusammensetzung die ein inhibierendes effekt auf die überproduktion und akkumulation der extrazellulären matrix hat |
| PT1109812E (pt) | 1998-08-27 | 2005-09-30 | Spirogen Ltd | Pirrolobenzodiazepinas |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| AU767878B2 (en) | 1998-09-17 | 2003-11-27 | Otsuka Pharmaceutical Co., Ltd. | LY6H gene |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1135519A4 (en) | 1998-12-02 | 2004-11-24 | Univ Pennsylvania | Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| DE19909357A1 (de) | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| DE19910108C2 (de) | 1999-03-08 | 2001-02-22 | Falk Fahrenholz | Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie |
| WO2000062076A1 (en) | 1999-04-13 | 2000-10-19 | Hsu Daniel K | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
| US6303576B1 (en) | 1999-04-21 | 2001-10-16 | Adherex Technologies Inc. | Compounds and methods for modulating β-catenin mediated gene expression |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU5849500A (en) | 1999-07-08 | 2001-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Apoptosis-associated factor |
| DE69903278D1 (de) | 1999-07-09 | 2002-11-07 | Inst Pasteur De Lille Lille | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit |
| DE60044149D1 (de) | 1999-08-06 | 2010-05-20 | S I S S A Scuola Internaz Supe | Transgene mäuse zur studierung von neurodegenerativen syndromen |
| ES2344189T3 (es) | 1999-09-03 | 2010-08-20 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer. |
| US6255054B1 (en) | 1999-09-09 | 2001-07-03 | Jacques Hugon | Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease |
| AU785216B2 (en) | 1999-09-17 | 2006-11-09 | Keio University | Humanin, a polypetide suppressing neuronal death |
| US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| CA2400117C (en) | 2000-02-14 | 2009-11-17 | Bf Research Institute, Inc. | Novel collagen-like protein clac, a precursor thereof, and genes encoding the same |
| IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| AU2001243622A1 (en) | 2000-03-13 | 2001-09-24 | La Jolla Institute For Allergy And Immunology | Monocyte chemoattractant activity of galectin-3 |
| US20060148712A1 (en) | 2000-03-13 | 2006-07-06 | Fu-Tong Liu | Monocyte chemoattractant activity of galectin-3 |
| JP2004501204A (ja) | 2000-06-28 | 2004-01-15 | プラナ バイオテクノロジー リミティッド | 神経毒オリゴマー |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| WO2002025246A1 (en) | 2000-09-21 | 2002-03-28 | Matsushita Electric Industrial Co., Ltd. | Scanning type probe microscope probe and method of producing the same, and a scanning type probe microscope having this probe and polymer processing method using the same |
| US7471798B2 (en) * | 2000-09-29 | 2008-12-30 | Knowles Electronics, Llc | Microphone array having a second order directional pattern |
| KR100395254B1 (ko) | 2000-10-30 | 2003-08-21 | (주)자리타 바이오텍 | 종양 발생 예측 키트 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| ATE394115T1 (de) | 2001-02-27 | 2008-05-15 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
| DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| WO2002084297A1 (en) | 2001-04-14 | 2002-10-24 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
| US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| DE10130247A1 (de) | 2001-06-22 | 2003-01-16 | Elegene Ag I Ins | Identifizierung von ses-3 sowie dessen Verwendungen |
| DE10130166A1 (de) | 2001-06-22 | 2003-01-16 | Elegene Ag I Ins | Identifizierung von ses-1 sowie dessen Verwendungen |
| US6831699B2 (en) | 2001-07-11 | 2004-12-14 | Chang Industry, Inc. | Deployable monitoring device having self-righting housing and associated method |
| JP4729717B2 (ja) | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ |
| DE60235996D1 (de) | 2001-09-07 | 2010-05-27 | Takeda Pharmaceutical | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| WO2003069347A2 (en) | 2002-02-14 | 2003-08-21 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of caps |
| EP1481007B1 (en) | 2002-03-04 | 2007-01-24 | Nymox Corporation | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom |
| ES2392247T3 (es) | 2002-03-05 | 2012-12-07 | Ramot At Tel-Aviv University Ltd. | Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2003080661A1 (en) | 2002-03-21 | 2003-10-02 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases |
| CN100360555C (zh) | 2002-04-19 | 2008-01-09 | 多伦多大学董事局 | 治疗阿尔茨海默氏病的免疫学方法及组合物 |
| WO2003091734A1 (en) | 2002-04-24 | 2003-11-06 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases |
| US20050032673A1 (en) | 2002-06-10 | 2005-02-10 | John Constance M. | Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease |
| EP1555938A4 (en) | 2002-06-21 | 2010-11-03 | Reuven Avrahom Cyrulnik | METHOD AND SYSTEM FOR IMAGING MACROMOLECULES |
| WO2004003563A2 (en) | 2002-06-27 | 2004-01-08 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases |
| US7141137B2 (en) | 2002-07-10 | 2006-11-28 | University Of Maine System Board Of Trustees | Method of making laminated wood beams with varying lamination thickness throughout the thickness of the beam |
| JP4414332B2 (ja) | 2002-07-12 | 2010-02-10 | アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物 |
| DE60336902D1 (de) | 2002-07-19 | 2011-06-09 | Cytos Biotechnology Ag | Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP1633786A4 (en) | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF |
| AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| MXPA05008156A (es) | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| WO2004070388A1 (en) | 2003-02-04 | 2004-08-19 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases |
| US7575747B2 (en) | 2003-02-10 | 2009-08-18 | Applied Molecular Evolution | Aβ binding molecules |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| JP2006522163A (ja) | 2003-04-07 | 2006-09-28 | グリコジェネシス， インク． | ガレクチンアンタゴニストの組成物と使用 |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| ES2246105B1 (es) | 2003-05-08 | 2007-03-01 | Araclon Biotech, S.L. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| WO2004111654A2 (en) | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| JP4888876B2 (ja) | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
| US7384523B2 (en) | 2003-07-10 | 2008-06-10 | Radiometer Medical Aps | Chloride ion selective membrane and sensor |
| ES2284018T3 (es) | 2003-07-28 | 2007-11-01 | Sig Technology Ltd. | Tapon vertedor con dispositivo cortador punzante para embases combinados o recipientes cerrados con meterial en laminas. |
| MXPA06001558A (es) | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico. |
| EP1660443B1 (en) | 2003-08-08 | 2009-03-04 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| JPWO2005023286A1 (ja) | 2003-09-05 | 2007-11-01 | 久光製薬株式会社 | アルツハイマー病の予防及び／又は治療のための薬剤 |
| AT413336B (de) | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| JP2007508810A (ja) | 2003-09-30 | 2007-04-12 | エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホトランスフェラーゼの神経変性疾患に関する診断的および治療的使用 |
| US7700823B2 (en) | 2003-10-02 | 2010-04-20 | Aventis Pharma S.A. | Transgenic animals exhibiting major disorders related to Alzheimer's disease |
| EP1685159B1 (en) * | 2003-10-03 | 2012-08-01 | Brigham & Women's Hospital | Tim-3 polypeptides |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2005071418A2 (en) | 2003-10-29 | 2005-08-04 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases |
| PT1692182E (pt) | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| US20050158321A1 (en) | 2003-12-17 | 2005-07-21 | Entelos, Inc. | Treatment of rheumatoid arthritis with galectin-3 antagonists |
| HRP20070241T3 (hr) | 2003-12-19 | 2007-07-31 | Bristol-Myers Squibb Company | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
| WO2005080435A1 (ja) | 2004-02-20 | 2005-09-01 | Immuno-Biological Laboratories Co., Ltd. | モノクローナル抗体およびその利用 |
| US8060179B1 (en) | 2006-11-16 | 2011-11-15 | Scientific Nanomedicine, Inc. | Biomagnetic detection and treatment of Alzheimer's Disease |
| WO2005085472A2 (en) | 2004-03-03 | 2005-09-15 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases |
| CA2558034A1 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| EP1723152B1 (en) | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| US7763249B2 (en) | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
| US7629443B2 (en) | 2004-06-02 | 2009-12-08 | New York Blood Center, Inc. | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1794313B1 (en) | 2004-06-21 | 2013-05-15 | Proteome Sciences Plc | Screening methods using c-abl, fyn and syk in combination with tau protein |
| US7460965B2 (en) | 2004-07-07 | 2008-12-02 | Mitsubishi Electric Corporation | Electric power calculating apparatus, electric power calculating method, tamper resistance evaluating apparatus, and tamper resistance evaluating method |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| WO2006014638A2 (en) | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| US20060024667A1 (en) | 2004-07-29 | 2006-02-02 | Karen Manucharyan | Compositions and methods for Alzheimer's disease |
| WO2006014944A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| CN1993378A (zh) | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| US8168188B1 (en) | 2004-08-11 | 2012-05-01 | Kyoto University | Antibody and utilization of the same |
| JP2008508893A (ja) | 2004-08-11 | 2008-03-27 | エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー | 形質膜ａｔｐアーゼの診断及び治療への使用 |
| GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| WO2006037800A1 (en) | 2004-10-08 | 2006-04-13 | Université de Liège | COMPLEMENTARY PEPTIDES FOR ß-AMYLOID 29-42 PEPTIDE |
| US9907485B2 (en) | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
| AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Ｎ末端にアミノ安息香酸単位を有するオーリスタチン |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US7632634B2 (en) | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| EP1891215B1 (en) | 2005-04-20 | 2009-10-28 | Dnavec Corporation | Highly safe intranasally administrable gene vaccines for treating alzheimer's disease |
| EP1879901B1 (en) | 2005-04-21 | 2009-12-23 | Spirogen Limited | Pyrrolobenzodiazepines |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| AU2006246382A1 (en) | 2005-05-05 | 2006-11-16 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| ATE534751T1 (de) | 2005-05-30 | 2011-12-15 | Takeda Pharmaceutical | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit |
| US20090133135A1 (en) | 2005-06-01 | 2009-05-21 | Evotec Neurosciences Gmbh | Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases |
| AR054510A1 (es) | 2005-06-14 | 2007-06-27 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden. |
| CA2610828A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| WO2006134128A2 (en) | 2005-06-16 | 2006-12-21 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases |
| CA2611054C (en) | 2005-06-17 | 2017-05-09 | National Research Council Of Canada | Novel a.beta.-binding polypeptides and derivatives and uses thereof |
| DE102005029729A1 (de) | 2005-06-24 | 2006-12-28 | Röchling Automotive AG & Co. KG | Verkleidungs- oder Gehäuseteil eines Fahrzeugs und Verfahren zu seiner Herstellung |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US20070021282A1 (en) | 2005-07-19 | 2007-01-25 | Karp Shaun A | Abdominal exercising and strength testing systems |
| CA2619725C (en) | 2005-08-18 | 2016-06-07 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
| US8507439B2 (en) | 2005-08-29 | 2013-08-13 | Angela Shashoua | Neuroprotective and neurorestorative method and compositions |
| EP1951892A4 (en) | 2005-11-22 | 2009-01-14 | Univ Pennsylvania | ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| WO2007064917A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US8034353B2 (en) | 2006-02-22 | 2011-10-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody |
| DK2514823T3 (en) | 2006-03-03 | 2018-07-23 | Promis Neurosciences Inc | Methods and compositions for treating and detecting failed SOD1-mediated diseases |
| JP2009531332A (ja) | 2006-03-23 | 2009-09-03 | ライフ テクノロジーズ コーポレーション | 癌細胞株のインビボイメージングのための方法及び試薬 |
| BRPI0709050B1 (pt) | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US20090220524A1 (en) | 2006-04-25 | 2009-09-03 | The University Of Tokyo | Therapeutic agents for alzheimer's disease and cancer |
| CA2653628C (en) | 2006-06-01 | 2015-07-14 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
| JP5365192B2 (ja) | 2006-07-06 | 2013-12-11 | 日本電気株式会社 | 半導体集積回路の階層設計方法および装置 |
| JP5959795B2 (ja) | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | 血液脳関門送達のための物質 |
| JP5207469B2 (ja) | 2006-09-06 | 2013-06-12 | 国立大学法人鳥取大学 | アルツハイマーの診断キット、診断マーカー及び病態指標の検出方法 |
| US20100330602A1 (en) | 2006-09-19 | 2010-12-30 | Emory University | Use of Soluble Galectin-3 (Gal-3) for Cancer Treatment |
| WO2008085564A2 (en) | 2006-09-20 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and methods involving truncated recombinant seven g-protein coupled receptors |
| WO2008060613A1 (en) | 2006-11-15 | 2008-05-22 | The J. David Gladstone Institutes | Methods and compositions for reducing amyloid beta levels |
| CA2668693A1 (en) | 2006-11-15 | 2008-05-22 | David E. Anderson | Therapeutic uses of tim-3 modulators |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8420591B2 (en) | 2006-12-08 | 2013-04-16 | Dana-Farber Cancer Institute, Inc. | MUC1 and galectin-3 |
| ES2777652T3 (es) | 2006-12-21 | 2020-08-05 | H Lundbeck As | Modulación de la actividad de proneurotrofinas |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| CN101636168B (zh) | 2007-01-09 | 2013-05-29 | 比奥根艾迪克Ma公司 | Sp35抗体及其用途 |
| AU2008204335B2 (en) | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
| CA2675847C (en) | 2007-01-18 | 2014-12-30 | Eli Lilly And Company | Pegylated a.beta. fab |
| WO2008112559A1 (en) | 2007-03-09 | 2008-09-18 | Regents Of The University Of California | Suppression of galectin-3 for treating an inflammatory condition |
| US8106015B2 (en) | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
| EP2140247B1 (en) | 2007-04-26 | 2012-06-27 | The Ludwig Institute for Cancer Research | Method for modulating activity of t lymphocytes |
| CA2719878C (en) | 2007-04-26 | 2017-08-29 | Yale University | Prion protein as a receptor for amyloid-beta oligomers |
| US9040045B2 (en) | 2007-05-14 | 2015-05-26 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
| CN101754960A (zh) | 2007-07-05 | 2010-06-23 | 先灵公司 | 四氢吡喃并色烯γ-分泌酶抑制剂 |
| CA2693216A1 (en) | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| US8993833B2 (en) | 2007-08-14 | 2015-03-31 | Duke University | Model of Alzheimer's Disease |
| WO2009027105A2 (en) | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| JP2010538068A (ja) | 2007-09-06 | 2010-12-09 | シェーリング コーポレイション | ガンマセクレターゼモジュレーター |
| US20100239570A1 (en) | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
| CA2703825A1 (en) | 2007-10-29 | 2009-05-07 | Innogenetics Nv | New antibodies specific of the .beta.-amyloid peptides and their uses as diagnostic agents or drugs |
| CN104098695B (zh) | 2007-10-29 | 2018-09-07 | 道健康生活医药株式会社 | 抗体及其应用 |
| CN101918564A (zh) | 2007-11-01 | 2010-12-15 | 弗·哈夫曼-拉罗切有限公司 | 非人类四元转基因动物 |
| EP2217604A1 (en) | 2007-11-05 | 2010-08-18 | Schering Corporation | Gamma secretase modulators |
| KR101397554B1 (ko) | 2007-11-09 | 2014-05-21 | 재단법인서울대학교산학협력재단 | 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법 |
| MX2010005282A (es) | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| EP2207568B1 (en) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| US8349579B2 (en) | 2007-12-13 | 2013-01-08 | Wayne State University | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer |
| EP2240602B1 (en) | 2008-01-07 | 2013-05-22 | Council of Scientific & Industrial Research | Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis |
| ITNA20080006A1 (it) | 2008-01-28 | 2009-07-29 | Consiglio Nazionale Ricerche | Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp |
| EP2246427B1 (en) | 2008-02-08 | 2016-11-30 | Immunas Pharma, Inc. | Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof |
| WO2009111240A1 (en) | 2008-02-29 | 2009-09-11 | Baxter International Inc. | ANTI-AMYLOID β ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO |
| FR2929292A1 (fr) | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
| US9908943B2 (en) | 2008-04-03 | 2018-03-06 | Vib Vzw | Single domain antibodies capable of modulating BACE activity |
| HRP20160177T1 (hr) | 2008-04-14 | 2016-03-25 | Alzinova Ab | Stabilni amiloidni beta monomeri i oligomeri |
| RU2518351C2 (ru) | 2008-05-09 | 2014-06-10 | Эббви Дойчланд Гмбх Унд Ко.Кг, | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения |
| EP2299812B1 (en) | 2008-05-27 | 2017-07-12 | Yale University | Targeting tgf-beta as a therapy for alzheimer's disease |
| WO2009151618A2 (en) | 2008-06-10 | 2009-12-17 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Methods and compositions for treating alzheimer's disease |
| EP2303926A1 (en) | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
| EP2303001A4 (en) | 2008-06-20 | 2016-07-13 | Janssen Biotech Inc | METHOD FOR VERIFYING THE EFFECTIVENESS OF TREATMENT OF NEUROLOGICAL ILLNESSES |
| ES2687259T5 (es) | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
| CA2729414C (en) | 2008-07-01 | 2017-08-22 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccine against amyloid folding intermediate |
| ES2524266T3 (es) | 2008-07-08 | 2014-12-04 | Incyte Corporation | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |
| JP2011527681A (ja) | 2008-07-08 | 2011-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | アルツハイマー病治療用ワクチン |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PE20110565A1 (es) | 2008-08-12 | 2011-09-02 | Zinfandel Pharmaceuticals Inc | Metodo de identificacion de factores de riesgo de la enfermedad |
| US8283322B2 (en) | 2008-08-15 | 2012-10-09 | Orthopeutics, Lp | Formulations for nonsurgical exogenous crosslink therapy |
| EP2346525A4 (en) | 2008-10-02 | 2012-05-09 | Celtaxsys Inc | METHODS OF MODULATION OF NEGATIVE CHIMOTAXIA OF IMMUNE CELLS |
| BRPI0919975A2 (pt) | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
| CN102308004A (zh) | 2008-10-30 | 2012-01-04 | 卡里斯生命科学卢森堡控股有限责任公司 | 评价rna图案的方法 |
| CA2742472A1 (en) | 2008-11-13 | 2010-05-20 | Schering Corporation | Gamma secretase modulators |
| US8673900B2 (en) | 2008-11-13 | 2014-03-18 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| DE102008037564A1 (de) | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| US8912145B2 (en) | 2008-11-28 | 2014-12-16 | Hokko Chemical Industry Co., Ltd. | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease |
| EP3115063A3 (en) * | 2008-12-03 | 2017-04-19 | The John Hopkins University | Galectin-3 and annexin-a2 as immunological target |
| US20120046181A1 (en) | 2008-12-19 | 2012-02-23 | Chu Nantes | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status |
| CA2747744A1 (en) | 2008-12-22 | 2010-07-01 | Theodros Asberom | Gamma secretase modulators |
| US20100196882A1 (en) | 2009-02-04 | 2010-08-05 | Avraham Raz | GALECTIN-3 nsSNP MARKER FOR CANCER |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| FR2942476B1 (fr) | 2009-02-20 | 2013-03-15 | Commissariat Energie Atomique | Composes de type pyridocarbazole et leurs applications |
| EP3978517A1 (en) | 2009-03-18 | 2022-04-06 | AC Immune SA | Method for therapeutic use |
| US9173928B2 (en) | 2009-03-26 | 2015-11-03 | Yoh Matsumoto | DNA vaccine for Alzheimer's disease |
| JP2010268789A (ja) | 2009-04-24 | 2010-12-02 | Kumamoto Univ | 細胞医薬の製造方法 |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| EP2258398A1 (en) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| CA2764545C (en) | 2009-06-15 | 2019-05-14 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Bace1 inhibitory antibodies |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| US20120100129A1 (en) | 2009-06-29 | 2012-04-26 | Gellerfors Paer | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders |
| EP2273273A1 (en) | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease |
| WO2011007560A1 (en) | 2009-07-15 | 2011-01-20 | Fuji Electric Systems Co., Ltd. | Super-junction semiconductor device |
| DK2462161T3 (en) | 2009-08-06 | 2017-06-06 | Immunas Pharma Inc | Antibodies specifically binding to A-beta oligomers and their use |
| MX2012001708A (es) | 2009-08-07 | 2012-05-22 | Kyowa Hakko Kirin Co Ltd | Anticuerpo humanizado anti-oligomero de amiloide b. |
| EA201270316A1 (ru) | 2009-08-25 | 2012-09-28 | БиДжи МЕДИСИН, ИНК. | Галектин-3 и сердечная ресинхронизирующая терапия |
| AU2010286501B2 (en) | 2009-08-28 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Antibodies that bind Tau oligomers |
| US8617549B2 (en) | 2009-09-11 | 2013-12-31 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Bispecific nanobodies as a therapeutic for alzheimer's disease |
| DE102009043750A1 (de) | 2009-09-30 | 2011-08-04 | Carl Zeiss Meditec AG, 07745 | Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge |
| EP2489675A4 (en) | 2009-10-16 | 2013-06-05 | Univ Kyoto | ANTIBODIES WITH RECOGNITION OF THE INVERTED STRUCTURE IN AN AMYLOID ß |
| US9757398B2 (en) | 2010-02-20 | 2017-09-12 | Euroespes Biotecnnologia, S.L. | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
| SG183854A1 (en) | 2010-03-03 | 2012-10-30 | Univ British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
| JP2013529181A (ja) | 2010-03-25 | 2013-07-18 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 神経障害を治療するための組成物および方法 |
| EP2451348A4 (en) | 2010-04-13 | 2013-07-31 | Baxter Int | USE OF THE VENTRICULAR MAGNITUDE RATE IN INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF MORBUS ALZHEIMER |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| JP5870400B2 (ja) | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス，インコーポレーテッド | 標的化ピロロベンゾジアゼピンコンジュゲート |
| WO2011148668A1 (ja) | 2010-05-25 | 2011-12-01 | 株式会社 島津製作所 | 大腸がんマーカーガレクチン、採血試料中のガレクチン濃度の分析方法及び大腸がんマーカーガレクチン検出キット |
| AU2011263642B2 (en) | 2010-06-11 | 2014-09-04 | Isarna Therapeutics Gmbh | Method for selective oligonucleotide modification |
| EP2593475B1 (en) | 2010-07-14 | 2016-03-02 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
| US10420923B1 (en) | 2010-08-10 | 2019-09-24 | Amiram Katz | Method and device for intrathecal administering of immunoglobulin |
| DK3339323T3 (da) | 2010-08-12 | 2020-01-20 | Lilly Co Eli | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf |
| WO2012036786A1 (en) | 2010-09-17 | 2012-03-22 | University Of L'aquila | Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease |
| JP2013542958A (ja) | 2010-11-03 | 2013-11-28 | イミュノジェン・インコーポレーテッド | アンサマイトシン誘導体を含む細胞傷害性剤 |
| US10117895B2 (en) | 2010-11-17 | 2018-11-06 | Ben-Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
| WO2012075037A1 (en) | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CA2823286C (en) | 2010-12-28 | 2020-01-28 | Dainippon Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| EP2508212A1 (en) | 2011-04-05 | 2012-10-10 | Universitätsklinikum Freiburg | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| KR101589135B1 (ko) | 2011-04-20 | 2016-01-29 | 주식회사 셀앤바이오 | 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도 |
| WO2012149607A1 (en) | 2011-05-03 | 2012-11-08 | Commonwealth Scientific And Industrial Research Organisation | Method for detection of a neurological disease |
| GB201108490D0 (en) | 2011-05-18 | 2011-07-06 | Ucl Business Plc | Methods and uses |
| JP2014515354A (ja) | 2011-05-19 | 2014-06-30 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Ｏｓｗ−１類似体および抱合体、ならびにそれらの使用 |
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| MX350954B (es) | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
| WO2013008402A1 (ja) | 2011-07-08 | 2013-01-17 | シャープ株式会社 | 薄膜トランジスタ基板及びそれを備えた表示装置 |
| GB201113482D0 (en) | 2011-08-04 | 2011-09-21 | Univ Liverpool | Assay |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| EP2758077B1 (en) | 2011-09-19 | 2018-12-19 | University Of The Witwatersrand, Johannesburg | Compounds for use in the treatment of alzheimer's disease |
| US9518101B2 (en) | 2011-09-19 | 2016-12-13 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| WO2013044099A1 (en) | 2011-09-23 | 2013-03-28 | Siemens Healthcare Diagnostics Inc. | Cell response assay for cancer and methods of producing and using same |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US8764695B2 (en) | 2012-09-28 | 2014-07-01 | Isaac Eliaz | Reduction of galectin-3 levels by plasmapheresis |
| US9549953B2 (en) | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| RU2545859C1 (ru) | 2011-12-08 | 2015-04-10 | Исаак ЭЛИАС | Уменьшение уровней галектина-3 посредством плазмафереза |
| AU2012351963A1 (en) | 2011-12-15 | 2014-06-26 | The United States of America, as represented by Secretary, Department of Health & Human Services | Identification of two novel biomarkers for Niemann-Pick disease type C |
| US20130164217A1 (en) | 2011-12-21 | 2013-06-27 | Meso Scale Technologies, Llc | Method of diagnosing, preventing and/or treating dementia & related disorders |
| KR20140068105A (ko) | 2011-12-29 | 2014-06-05 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용 |
| CA2862999A1 (en) | 2012-01-11 | 2013-07-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific antibody fragments for neurological disease proteins and methods of use |
| SG11201404741VA (en) | 2012-02-07 | 2014-09-26 | Global Bio Therapeutics Usa Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| ES2617853T3 (es) | 2012-02-27 | 2017-06-20 | Universitat De Barcelona | Compuestos resistentes a proteasas útiles como transportadores a través de la barrera hematoencefálica y construcciones de transportador-carga |
| ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
| KR20140145173A (ko) | 2012-03-26 | 2014-12-22 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커 |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| WO2013169890A1 (en) | 2012-05-08 | 2013-11-14 | Bg Medicine, Inc. | Systems and methods for assessing disease risk, status, and prognosis |
| DK3269736T3 (da) | 2012-05-10 | 2020-01-13 | Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin | Konformationsspecifikke antistoffer mod oligomerer af amyloid beta |
| EP3925627A1 (en) | 2012-05-15 | 2021-12-22 | Concortis Biosystems, Corp | Drug-conjugates and uses thereof |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| FR2994803B1 (fr) | 2012-08-30 | 2016-02-26 | Oreal | Modulation de la forme des fibres keratiniques |
| CA2883130A1 (en) | 2012-08-31 | 2014-03-06 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of alzheimer's disease |
| MX2015002947A (es) | 2012-09-07 | 2015-09-23 | Genentech Inc | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. |
| WO2014043708A1 (en) * | 2012-09-17 | 2014-03-20 | Traber Peter G | Method for enhancing specific immunotherapies in cancer treatment |
| CA3247166A1 (en) | 2012-10-04 | 2026-03-02 | Research Development Foundation | Serine protease molecules and therapies |
| EP2906597B1 (en) | 2012-10-15 | 2020-04-08 | Medimmune Limited | Antibodies to amyloid beta |
| US20150301058A1 (en) | 2012-11-26 | 2015-10-22 | Caris Science, Inc. | Biomarker compositions and methods |
| US9066928B1 (en) | 2012-12-04 | 2015-06-30 | University Of Kentucky Research Foundation | Method, composition, and kit useful for treatment of alzheimer's disease |
| KR20150119848A (ko) | 2012-12-21 | 2015-10-26 | 바이오얼라이언스 씨.브이. | 친수성 자기-희생 링커 및 그것의 포합체 |
| US9433665B2 (en) | 2013-01-11 | 2016-09-06 | Cyvax, Inc. | Vaccines for protection from and treatment of alzheimer's disease |
| WO2014123186A1 (ja) | 2013-02-06 | 2014-08-14 | 公立大学法人横浜市立大学 | 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療 |
| DK2961426T3 (da) | 2013-02-26 | 2019-12-02 | Baxalta GmbH | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g |
| JP6499087B2 (ja) | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| US10450354B2 (en) | 2013-03-12 | 2019-10-22 | Molecular Templates, Inc. | CD20-binding immunotoxins for inducing cellular internalization and methods using same |
| AU2014244245C1 (en) | 2013-03-13 | 2018-04-19 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| CA2903091C (en) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2014151747A1 (en) | 2013-03-15 | 2014-09-25 | Ramot At Tel Aviv University Ltd. | Methods and compositions with immune therapy for treatment of dementia |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| US9937231B2 (en) | 2013-03-27 | 2018-04-10 | The General Hospital Corporation | Methods and agents for treating Alzheimer's disease |
| LT2994160T (lt) | 2013-05-06 | 2019-08-26 | Baxalta Incorporated | Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g |
| AU2014274044B2 (en) | 2013-05-31 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat Alzheimer's Disease |
| EP3013355B1 (en) | 2013-06-25 | 2019-08-07 | ICM - Institut du Cerveau et da la Moelle Epinière | Il-2 for use in treating alzheimer disease and related disorders |
| WO2015031084A1 (en) | 2013-08-28 | 2015-03-05 | Jianfeng Cai | Methods of synthesizing y-aapeptides, y-aapeptide building blocks, y-aapeptide libraries, and y-aapeptide inhibitors of ab40 aggregates |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| US9725468B2 (en) | 2013-09-13 | 2017-08-08 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as BACE inhibitors, compositions, and their use |
| WO2015051850A1 (en) | 2013-10-11 | 2015-04-16 | Universität Für Bodenkultur Wien | Compositions containing galectin-3 modulators for the treatment of bone disorders |
| EP3057610B1 (en) | 2013-10-15 | 2021-09-22 | Sorrento Therapeutics, Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| GB201319761D0 (en) | 2013-11-08 | 2013-12-25 | Nordic Bioscience As | Biomarkers of disease progression |
| SI3083680T1 (sl) | 2013-12-20 | 2020-06-30 | F. Hoffmann-La Roche Ag | Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe |
| US9989541B2 (en) | 2013-12-27 | 2018-06-05 | Dignity Health | Diagnosing and treating alzheimer's disease |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| IL285403B2 (en) | 2014-01-27 | 2023-10-01 | Molecular Templates Inc | Polypeptides that remove an epitope for MHC group I |
| US20160177284A1 (en) | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
| US20210138076A2 (en) | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| EP3102245B1 (en) | 2014-02-05 | 2021-09-08 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| SG10201901076WA (en) | 2014-02-08 | 2019-03-28 | Genentech Inc | Methods of treating alzheimer's disease |
| WO2015138438A1 (en) | 2014-03-10 | 2015-09-17 | La Jolla Pharmaceutical Company | Compositions and methods for treating kidney disorders |
| JP6935195B2 (ja) | 2014-03-11 | 2021-09-15 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
| SI3604333T1 (sl) | 2014-03-11 | 2021-08-31 | Molecular Templates, Inc. | Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38 |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| CR20160455A (es) | 2014-04-10 | 2016-12-16 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA |
| WO2015159963A1 (ja) | 2014-04-16 | 2015-10-22 | 協和発酵キリン株式会社 | ヒトｃｓｆの毒性を測定する方法 |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| US11219627B2 (en) | 2014-05-16 | 2022-01-11 | Synaptec Development Llc | Clearance of amyloid beta |
| EP3137488B1 (en) | 2014-06-11 | 2019-01-02 | Molecular Templates, Inc. | Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same |
| US20150377905A1 (en) | 2014-06-25 | 2015-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosis of kawasaki disease |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| EP3161671A4 (en) | 2014-06-30 | 2017-06-28 | Microsoft Technology Licensing, LLC | Managing data with flexible schema |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| JP6913018B2 (ja) | 2014-07-08 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| HRP20210680T1 (hr) | 2014-07-10 | 2021-06-11 | Bioarctic Ab | POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL |
| RS65573B1 (sr) | 2014-08-04 | 2024-06-28 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije |
| RS62713B1 (sr) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
| EP3182130A4 (en) | 2014-08-14 | 2018-04-18 | Hiroshima University | Method and kit for determining risk of preterm birth and/or birth of low-birth-weight baby |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| SG11201701821QA (en) | 2014-09-15 | 2017-04-27 | Genentech Inc | Antibody formulations |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US10328051B2 (en) | 2014-09-22 | 2019-06-25 | Zoser B. Salama | Proline or proline derivatives for the treatment of dementia |
| JP2017531571A (ja) | 2014-10-01 | 2017-10-26 | ダウ グローバル テクノロジーズ エルエルシー | 多層構造及びそれから作製される熱成形物品 |
| US9921230B2 (en) | 2014-10-08 | 2018-03-20 | Rhode Island Hospital | Methods for diagnosis and treatment of concussion or brain injury |
| WO2016059453A1 (en) | 2014-10-16 | 2016-04-21 | Fundacion Fraunhofer Chile Research | Biomarkers and therapeutic targets for alzheimer's disease |
| EP3215845A4 (en) | 2014-11-04 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
| HRP20210124T1 (hr) | 2014-11-19 | 2021-03-19 | Axon Neuroscience Se | Humanizirana tau antitijela u alzheimerovoj bolesti |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US9827308B2 (en) | 2014-12-10 | 2017-11-28 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2016120843A1 (en) | 2015-01-29 | 2016-08-04 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| CA2976005A1 (en) | 2015-02-06 | 2016-08-11 | Cell Idx, Inc. | Antigen-coupled immunoreagents |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| GB201504432D0 (en) | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3274010B1 (en) | 2015-03-27 | 2019-10-02 | Eliaz Therapeutics, Inc. | Patient selective apheresis |
| US12109346B2 (en) | 2015-03-27 | 2024-10-08 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| GB201505239D0 (en) | 2015-03-27 | 2015-05-13 | Neuro Bio Ltd | Antibody |
| RU2745898C2 (ru) | 2015-04-15 | 2021-04-02 | Анаптисбайо, Инк. | Антитела, направленные против рецептора интерлейкина 36 (il-36r) |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| CN107592812A (zh) | 2015-05-11 | 2018-01-16 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
| GB201508276D0 (en) | 2015-05-14 | 2015-06-24 | Electrophoretics Ltd | A casein kinase 1 delta inhibitor |
| RU2715597C2 (ru) | 2015-05-29 | 2020-03-02 | Эббви Инк. | Антитела к cd40 и способы их применения |
| HUE051246T2 (hu) | 2015-05-30 | 2021-03-01 | Molecular Templates Inc | Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák |
| UA125496C2 (uk) | 2015-06-08 | 2022-04-13 | Дебіофарм Інтернаціонал, С.А. | Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20 |
| US10203342B2 (en) | 2015-06-11 | 2019-02-12 | Nanosomix, Inc. | Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders |
| CN107810196B (zh) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| CR20210429A (es) | 2015-06-24 | 2021-09-24 | Hoffmann La Roche | ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562) |
| IL297460A (en) | 2015-06-30 | 2022-12-01 | Nanotics Llc | Compositions and methods related to absorbent particles |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CN108135986B (zh) | 2015-08-13 | 2022-07-29 | 纽约大学 | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
| CN108137679B (zh) | 2015-08-13 | 2022-07-19 | 纽约大学 | 对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
| EP3337514B8 (en) | 2015-08-18 | 2022-04-06 | Rakuten Medical, Inc. | Composition comprising a conjugate comprising a phthalocyanine dye linked to a targeting molecule for photoimmunotherapy |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3347486A4 (en) | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE |
| WO2017050803A1 (en) | 2015-09-25 | 2017-03-30 | Universität Duisburg-Essen | Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease |
| JP7628764B2 (ja) | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | Ａｓｇｒ阻害剤 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| JP2019501115A (ja) | 2015-10-28 | 2019-01-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与 |
| EP3374368B1 (en) | 2015-11-09 | 2022-06-01 | Galecto Biotech AB | 1,1'-sulfanediyl-di-beta-d-galactopyranosides as inhibitors of galectins |
| AU2016368469B2 (en) | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
| AU2016383475B2 (en) | 2015-12-28 | 2024-02-22 | Innate Pharma | Variable regions for NKp46 binding proteins |
| CN108779182A (zh) | 2015-12-28 | 2018-11-09 | 麻省理工学院 | 具有恒定区突变的双特异性抗体及其用途 |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| JP2019515874A (ja) | 2016-03-01 | 2019-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 改変された細胞死誘導を有するオビヌツズマブ変異体 |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| WO2017172757A1 (en) | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| EP3436037A4 (en) | 2016-03-31 | 2019-12-04 | University of Southern California | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| EP3464639A4 (en) | 2016-05-31 | 2020-01-01 | Goetzl, Edward, J. | DIAGNOSTIC METHOD AND DRUG EFFECT TEST METHOD FOR DEMENTIA WITH THE USE OF ASTROCYTE-DERIVED EXOSOMES |
| WO2017218911A1 (en) | 2016-06-17 | 2017-12-21 | Abbott Laboratories | BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) |
| CN119139329A (zh) | 2016-06-28 | 2024-12-17 | 应急生物防御行动兰辛有限责任公司 | 布林西多福韦的制剂 |
| KR102551971B1 (ko) | 2016-07-12 | 2023-07-07 | 하. 룬드벡 아크티에셀스카브 | 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 |
| US12123874B2 (en) | 2016-07-18 | 2024-10-22 | Cell Idx, Inc. | Reagent compounds, compositions, kits, and methods for amplified assays |
| EP3487524A4 (en) | 2016-07-20 | 2020-03-25 | Anahit Ghochikyan | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
| CN107652342A (zh) | 2016-07-23 | 2018-02-02 | 江苏万高药业股份有限公司 | 核苷氨基磷酸酯类前药的多晶型及其制备方法 |
| US10076552B2 (en) | 2016-08-09 | 2018-09-18 | DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. | Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof |
| EP3502248B1 (en) | 2016-08-09 | 2024-05-29 | National University Corporation Tokyo Medical and Dental University | Antibodies against hmgb1, and composition comprising same for treating or preventing alzheimer's disease |
| DK3922279T3 (da) | 2016-08-30 | 2025-02-03 | Dana Farber Cancer Inst Inc | Præparater til lægemiddelafgivelse og anvendelse heraf |
| WO2018058098A1 (en) | 2016-09-26 | 2018-03-29 | Yale University | Compounds and methods for treating or preventing alzheimer's disease |
| US10662226B2 (en) | 2016-10-28 | 2020-05-26 | The Regents of the University of Caiifomia | Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| ES2834484T3 (es) | 2016-11-21 | 2021-06-17 | Univ Ruhr Bochum | Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| JP7075134B2 (ja) | 2016-12-07 | 2022-05-25 | モレキュラー テンプレーツ，インク． | 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子 |
| JP2020504105A (ja) | 2016-12-19 | 2020-02-06 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なｔｎｆｒアゴニストおよびその使用 |
| MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US11634486B2 (en) | 2016-12-23 | 2023-04-25 | Bluefin Biomedicine, Inc. | Anti-SEZ6L2 antibodies and antibody drug conjugates |
| JP7082424B2 (ja) | 2017-01-25 | 2022-06-08 | モレキュラー テンプレーツ，インク． | 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子 |
| KR20240095466A (ko) | 2017-01-30 | 2024-06-25 | 내션얼 리서치 카운슬 오브 캐나다 | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US10473672B2 (en) | 2017-02-09 | 2019-11-12 | Kaohsiung Chang Gung Memorial Hospital | Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers |
| WO2018156250A1 (en) | 2017-02-21 | 2018-08-30 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
| WO2018156617A2 (en) | 2017-02-22 | 2018-08-30 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer / biomacromolecule conjugates |
| IL269531B2 (en) | 2017-03-27 | 2024-10-01 | Hoffmann La Roche | Improved antigen binding receptors |
| SG11201908772TA (en) | 2017-03-31 | 2019-10-30 | Genmab Holding B V | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| US20230399414A1 (en) | 2017-03-31 | 2023-12-14 | Genmab Holding B.V, | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN108728465A (zh) | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用 |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| US11518810B2 (en) | 2017-05-08 | 2022-12-06 | Shanghai Jmt-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| CN111032670A (zh) | 2017-05-12 | 2020-04-17 | 卡莱克汀科学有限责任公司 | 用于治疗系统性胰岛素抗性病症的化合物及其用途 |
| AU2018269498A1 (en) | 2017-05-18 | 2019-10-24 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| US11214835B1 (en) | 2017-06-06 | 2022-01-04 | University Of South Florida | Methods and compositions for diagnosis and management of neurodegerative diseases |
| SG11201912010XA (en) | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
| CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| US10662246B2 (en) | 2017-07-10 | 2020-05-26 | New York University | Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy |
| SG11202000105QA (en) | 2017-07-14 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-cd166 antibodies and uses thereof |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| US20190029970A1 (en) | 2017-07-31 | 2019-01-31 | The Chinese University Of Hong Kong | Fatty acid conjugated nanoparticles and uses thereof |
| WO2019028357A1 (en) | 2017-08-03 | 2019-02-07 | Galectin Sciences, Llc | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF |
| CN119798437A (zh) | 2017-08-08 | 2025-04-11 | 豪夫迈·罗氏有限公司 | 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗 |
| CN107881160A (zh) | 2017-08-11 | 2018-04-06 | 百奥泰生物科技(广州)有限公司 | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| EP3466975A1 (en) | 2017-10-05 | 2019-04-10 | Laboratoire Français du Fractionnement et des Biotechnologies | A specific binding molecule directed against galectin-3 protein |
| US20200330592A1 (en) | 2017-10-09 | 2020-10-22 | Keith Black | Compositions and methods of treating alzheimer's and other amyloid related diseases |
| AU2018350992A1 (en) | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| CN111770761B (zh) | 2017-10-25 | 2024-07-09 | 爱兰细胞技术公司 | H1.0k180me2抗体、其制造方法和用途 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| WO2019094679A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of California | BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs) |
| AU2018375356A1 (en) | 2017-11-29 | 2020-05-14 | Neotope Neuroscience Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
| PT3720431T (pt) | 2017-12-06 | 2024-12-05 | Basf As | Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica |
| EP3729081B1 (en) | 2017-12-21 | 2025-02-19 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
| CN109985231A (zh) | 2018-01-02 | 2019-07-09 | 上海清流生物医药科技有限公司 | 一种蛋白在制备预防和治疗痴呆症的药物中的应用 |
| WO2019137922A1 (en) | 2018-01-09 | 2019-07-18 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation |
| KR101868343B1 (ko) | 2018-01-16 | 2018-06-18 | 재단법인대구경북과학기술원 | 콧물 시료의 베타 아밀로이드 올리고머를 이용한 알츠하이머 질환의 진행 단계 스크리닝용 조성물 및 이를 이용한 알츠하이머 질환의 진행 단계 스크리닝 방법 |
| EP3746123A4 (en) | 2018-02-01 | 2021-12-01 | Memorial Sloan-Kettering Cancer Center | ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE |
| WO2019161384A1 (en) | 2018-02-19 | 2019-08-22 | New York University | Tau single domain antibodies |
| US11819488B2 (en) | 2018-02-23 | 2023-11-21 | Rhnanopharma | Nanosuspensions of salsalate and methods of using the same |
| EP3755350A4 (en) | 2018-02-23 | 2021-11-03 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER |
| EP3759145A4 (en) | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| WO2019186276A2 (en) | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
| AU2019243579B2 (en) | 2018-03-29 | 2024-05-09 | Microvascular Therapeutics LLC | Compositions and methods of detecting and treating Alzheimer's disease |
| EP3773916A4 (en) | 2018-04-04 | 2021-12-15 | TrueBinding, Inc. | PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| JP7318948B2 (ja) | 2018-04-13 | 2023-08-01 | 国立大学法人京都大学 | 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬 |
| LT3781200T (lt) | 2018-04-16 | 2024-08-12 | F. Hoffmann-La Roche Ag | Chelatintų radionuklidų antikūnai |
| WO2019207159A1 (en) | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| EP3793686A1 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| CA3100896C (en) | 2018-05-30 | 2023-08-29 | National Health Research Institutes | Anti-abeta antibodies and uses thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| RS67299B1 (sr) | 2018-06-19 | 2025-11-28 | Univ Pablo De Olavide | Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteina |
| EP3810142A4 (en) | 2018-06-20 | 2022-03-30 | Sanford Burnham Prebys Medical Discovery Institute | ANTIRETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US20220267460A1 (en) | 2018-07-11 | 2022-08-25 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
| CA3107370A1 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN112584863B (zh) | 2018-08-17 | 2025-10-28 | Ab工作室有限公司 | 催化抗体和其使用方法 |
| CN112703200B (zh) | 2018-08-31 | 2025-01-10 | 布鲁姆科技株式会社 | 针对糖化终产物的抗体及其应用 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| EP3852753A4 (en) | 2018-09-18 | 2022-06-08 | 1Globe Biomedical Co., Ltd. | TREATMENT OF NONALCOHOLIC FAT LIVER DISEASE |
| JP7475687B2 (ja) | 2018-09-21 | 2024-04-30 | 国立大学法人 東京医科歯科大学 | ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
| IL281979B2 (en) | 2018-10-04 | 2025-09-01 | Georg August Universit?T G?Ttingen Stiftung ?Ffentlichen Rechts Universit?Tsmedizin | Human antibodies that bind amyloid peptides |
| EP3861352A4 (en) | 2018-10-04 | 2022-08-03 | University of Manitoba | NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| JP2022505101A (ja) | 2018-10-18 | 2022-01-14 | ファンダメンタル ファーマ ゲーエムベーハー | Ｎｍｄａ受容体媒介毒性を調節するための新規の方法 |
| EP3643319A1 (en) | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| CN112996562A (zh) | 2018-10-29 | 2021-06-18 | 赛克洛治疗股份有限公司 | 治疗阿尔茨海默病的方法 |
| JP2022509372A (ja) | 2018-10-29 | 2022-01-20 | バイオジェン・エムエイ・インコーポレイテッド | 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント |
| US12534526B2 (en) | 2018-11-07 | 2026-01-27 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A antibody, preparation method therefor and application thereof |
| EP3887401A2 (en) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| JP2022510218A (ja) | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| AU2019393739B2 (en) | 2018-12-04 | 2025-06-26 | The Brain Protection Company PTY LTD | Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use |
| US12365724B2 (en) | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| MX2021007320A (es) | 2018-12-21 | 2021-07-07 | Hoffmann La Roche | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor. |
| JP2022037257A (ja) | 2018-12-27 | 2022-03-09 | クリニジェン株式会社 | アルツハイマー病を治療又は予防する為の抗ウイルス剤及びその使用 |
| AU2020207962A1 (en) | 2019-01-18 | 2021-07-22 | University Of Southern California | Methods and compositions to improve the safety and efficacy of cellular therapies |
| WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
| CN113711036B (zh) * | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN111518205B (zh) | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| CN113597431B (zh) | 2019-02-08 | 2025-02-21 | 普罗塞纳生物科学有限公司 | 识别Tau的抗体 |
| CN113710269A (zh) | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
| PL240124B1 (pl) | 2019-02-21 | 2022-02-21 | Univ Jagiellonski | Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą |
| US12441793B2 (en) | 2019-02-22 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| US20220233705A1 (en) | 2019-02-26 | 2022-07-28 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| WO2020185676A1 (en) | 2019-03-08 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
| AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| MA55491A (fr) | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica Nv | Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations |
| BR112021019471A2 (pt) | 2019-03-29 | 2022-04-26 | Torque Therapeutics Inc | Composições imunoterapêuticas e uso das mesmas |
| EP3947395A1 (en) | 2019-03-29 | 2022-02-09 | ImmunoGen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| US20220184127A1 (en) | 2019-04-08 | 2022-06-16 | Phanes Therapeutics, Inc. | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
| MA55902A (fr) | 2019-04-24 | 2022-03-16 | Ac Immune Sa | Administration hétérologue de vaccins tau |
| TW202106708A (zh) | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
| HUE065484T2 (hu) | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| AU2020270071A1 (en) | 2019-05-06 | 2021-10-21 | The Regents Of The University Of California | Non-HLA markers of transplant rejection |
| CN114040772A (zh) | 2019-05-09 | 2022-02-11 | 约翰内斯堡威特沃特斯兰德大学 | 降低Tau(τ)蛋白和/或磷酸化Tau(τ)蛋白的浓度的方法 |
| CN114206340A (zh) | 2019-05-14 | 2022-03-18 | 豪夫迈·罗氏有限公司 | 使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法 |
| WO2020236679A1 (en) | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| JP7716992B2 (ja) | 2019-06-04 | 2025-08-01 | ヴェルソー セラピューティクス， インコーポレイテッド | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
| CN112111012B (zh) | 2019-06-20 | 2023-07-04 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| EP3986439A4 (en) | 2019-06-21 | 2023-10-04 | University of Kansas | COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF BRAIN DISEASES |
| BR112021026089A2 (pt) | 2019-06-26 | 2022-03-22 | Amunix Pharmaceuticals Inc | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos |
| JP7788859B2 (ja) | 2019-06-26 | 2025-12-19 | メモリアル スローン ケタリング キャンサー センター | がんを処置するための抗ｃｄ３３抗体 |
| US20220380454A1 (en) | 2019-06-28 | 2022-12-01 | The Regents Of The University Of California | Methods and compositions for treating alzheimer's disease |
| EP3995582B1 (en) | 2019-07-01 | 2026-04-22 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| EP3994159A4 (en) | 2019-07-05 | 2023-08-09 | University of Florida Research Foundation, Incorporated | METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN |
| JP7194085B2 (ja) | 2019-07-09 | 2022-12-21 | 日立Astemo株式会社 | 操舵制御装置、操舵制御方法、及び操舵制御システム |
| US12403309B2 (en) | 2019-07-15 | 2025-09-02 | Cochlear Limited | Transcutaneous power and data communication link |
| CN121800915A (zh) | 2019-07-16 | 2026-04-07 | 赛诺菲 | 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 |
| DE102019119426A1 (de) | 2019-07-17 | 2021-01-21 | Endress+Hauser SE+Co. KG | Feldgerät der Automatisierungstechnik |
| EP4002490A4 (en) | 2019-07-17 | 2023-04-05 | Kabushiki Kaisha Toshiba | SOLAR BATTERY MODULE AND TANDEM SOLAR BATTERY |
| US20220275037A1 (en) | 2019-07-19 | 2022-09-01 | Dingding MO | ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF |
| JP7802651B2 (ja) | 2019-08-07 | 2026-01-20 | アクアラン セラピューティクス コーポレーション | 抗ｎａｍｐｔ抗体及びその用途 |
| AU2020329616B2 (en) | 2019-08-14 | 2026-03-12 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Caspase-2 variants |
| US20240059785A1 (en) | 2019-08-30 | 2024-02-22 | Qilu Puget Sound Biotherapeutics Corporation | Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof |
| CN114450406B (zh) | 2019-09-09 | 2025-07-15 | 武汉友芝友生物制药股份有限公司 | 一种断裂型内含肽、使用其的重组多肽的制备方法 |
| MX2022002852A (es) | 2019-09-09 | 2022-03-25 | Axon Neuroscience Se | Biomarcadores y tratamientos de la enfermedad de alzheimer y deterioro cognitivo leve. |
| AU2020344553A1 (en) | 2019-09-09 | 2022-04-07 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| EP4438057A3 (en) | 2019-09-12 | 2025-01-01 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
| US11202068B2 (en) | 2019-09-16 | 2021-12-14 | Mediatek Inc. | Method and apparatus of constrained cross-component adaptive loop filtering for video coding |
| BR112022005044A2 (pt) | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
| CN114616031A (zh) | 2019-09-19 | 2022-06-10 | Igm生物科学股份有限公司 | 对靶标密度高的细胞的选择性增强的多聚体抗体 |
| US20240050562A1 (en) | 2019-10-04 | 2024-02-15 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| US20240050529A1 (en) | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| CN112641953A (zh) | 2019-10-10 | 2021-04-13 | 复旦大学 | 一种靶向功能分子修饰的抗体复合物 |
| CA3158513A1 (en) | 2019-10-22 | 2021-04-29 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| ES2821599A1 (es) | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
| WO2021087245A1 (en) | 2019-10-30 | 2021-05-06 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
| GB201915855D0 (en) | 2019-10-31 | 2019-12-18 | Univ Oxford Innovation Ltd | An extracellular vesicle |
| IL292863A (en) | 2019-11-13 | 2022-07-01 | Amunix Pharmaceuticals Inc | Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use |
| JP7843702B2 (ja) | 2019-11-28 | 2026-04-10 | マックマスター、ユニバーシティー | 細胞外小胞をプログラムするための組換えポリペプチド |
| JP7835441B2 (ja) | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 |
| EP4076271A2 (en) | 2019-12-17 | 2022-10-26 | Cirlo GmbH | Tubular shaped elongated catheter device for interacting with components of bodily fluids |
| EP4085251B1 (en) | 2020-01-02 | 2024-07-31 | F. Hoffmann-La Roche AG | Method for determining the amount of a therapeutic antibody in the brain |
| IL294486A (en) | 2020-01-13 | 2022-09-01 | Truebinding Inc | Antibodies against gal3 and methods of use |
| US20230074657A1 (en) | 2020-01-21 | 2023-03-09 | Shanghai Henlius Biotech, Inc. | Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| KR20220137674A (ko) | 2020-02-05 | 2022-10-12 | 스미토모 파마 가부시키가이샤 | 타우병증 및 인지증 관련 질환의 판정약 및 판정 방법 |
| AU2021220865A1 (en) | 2020-02-12 | 2022-09-01 | The Scripps Research Institute | Long-acting GM-CSF and methods of use |
| WO2021163681A2 (en) | 2020-02-14 | 2021-08-19 | The Trustees Of Columbia University In The City Of New York | Combination of retromer pharmacological chaperones and exogenous retromer for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders |
| WO2021167723A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Chimeric scavenger receptors targeted to phosphorylated tau (ptau) and uses thereof |
| US12595311B2 (en) | 2020-03-02 | 2026-04-07 | The Regents Of The University Of California | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| GB202003428D0 (en) | 2020-03-10 | 2020-04-22 | Univ Dundee | IL-10 mutiens |
| CN113384710A (zh) | 2020-03-14 | 2021-09-14 | 杭州星鳌生物科技有限公司 | 新型免疫激动剂复合物的组成及其在抗多种疾病药物中的应用 |
| EP4592310A2 (en) | 2020-03-16 | 2025-07-30 | Angeles Therapeutics, Inc. | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| US20230104705A1 (en) | 2020-03-17 | 2023-04-06 | Cellular Biomedicine Group Inc. | Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| US20230212255A1 (en) | 2020-03-17 | 2023-07-06 | Cellular Biomedicine Group Inc. | Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof |
| EP4121004A1 (en) | 2020-03-20 | 2023-01-25 | University Of Heidelberg | Colloidal carrier systems for transfer of agents to a desired site of action |
| US20230107479A1 (en) | 2020-03-23 | 2023-04-06 | G3 Pharmaceuticals, Inc. | Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection |
| KR20220156934A (ko) | 2020-03-24 | 2022-11-28 | 탈렌젠 인터내셔널 리미티드 | 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물 |
| WO2021190558A1 (zh) | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | 一种治疗阿尔茨海默病的方法和药物 |
| US20230141177A1 (en) | 2020-03-31 | 2023-05-11 | The University Of British Columbia | Antibodies to misfolded amyloid beta |
| EP4132584A4 (en) | 2020-04-07 | 2024-05-01 | The Regents Of The University Of California | PRODUCTION OF SYNTHETIC EXOSOMES FOR THE DELIVERY OF THERAPEUTICS AND NON-CNS |
| CA3174646A1 (en) | 2020-04-07 | 2021-10-14 | Pieter Muntendam | Methods and compositions for preventing and treating retinal nerve damage |
| CN115702003A (zh) | 2020-04-23 | 2023-02-14 | 瑞美德生物医药科技有限公司 | 趋化因子受体4(cxcr4)拮抗剂抗体 |
| JP7785016B2 (ja) | 2020-04-24 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ＣＤ７９ｂ免疫抱合体の使用方法 |
| EP4400515A3 (en) | 2020-04-24 | 2024-10-23 | F. Hoffmann-La Roche AG | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
| JP2023526500A (ja) | 2020-05-19 | 2023-06-21 | オター プロシーナ リミテッド | アルツハイマー病の処置のためのマルチエピトープワクチン |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| EP4157241A4 (en) | 2020-05-29 | 2025-01-08 | The Regents of the University of California | AGENTS AND METHODS FOR THE TREATMENT OF TAUOPATHIES |
| AU2021283345A1 (en) | 2020-06-02 | 2023-02-02 | Dynamicure Biotechnology Llc | Anti-CD93 constructs and uses thereof |
| CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US20230235036A1 (en) | 2020-06-05 | 2023-07-27 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Acvr1 (alk2) receptor inhibition to treat neurological diseases |
| KR102225447B1 (ko) | 2020-06-16 | 2021-03-08 | 부산대학교 산학협력단 | 구강 세균의 군집을 이용한 알츠하이머 진단용 바이오마커 및 이의 용도 |
| MX2022015203A (es) | 2020-06-19 | 2023-01-05 | Hoffmann La Roche | Moleculas de union al dominio fc de activacion inmunitaria. |
| CN116547299A (zh) | 2020-06-25 | 2023-08-04 | 米迪缪尼有限公司 | 使用结合淀粉样蛋白β1-42肽的抗体来预防神经元轴突损伤 |
| US20210403644A1 (en) | 2020-06-29 | 2021-12-30 | University Of South Carolina | Method For The Degradation Of Endogenous Protein |
| EP4173636A4 (en) | 2020-06-30 | 2024-08-28 | Shionogi & Co., Ltd | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| JP2023535677A (ja) | 2020-07-10 | 2023-08-21 | バイオモレキュラー・ホールディングス・エルエルシー | 四面体抗体 |
| US20230285588A1 (en) | 2020-07-20 | 2023-09-14 | Neotx Therapeutics Ltd. | Superantigen conjugate for use in methods and compositions for treating cancer |
| AR123008A1 (es) | 2020-07-20 | 2022-10-19 | Genentech Inc | Métodos para la caracterización de anticuerpos de tipo del medio hacia abajo |
| JP2023535022A (ja) | 2020-07-21 | 2023-08-15 | アムニクス ファーマシューティカルズ， インコーポレイテッド | 活性化可能な治療剤に関する組成物および方法 |
| US20230322935A1 (en) | 2020-07-29 | 2023-10-12 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| BR112023000848A2 (pt) | 2020-07-30 | 2023-02-07 | Unigen Inc | Composição de bioflavonoide padronizada para regulação de homeostase de mecanismo de defesa de hospedeiro |
| JP2023536851A (ja) | 2020-07-30 | 2023-08-30 | アナプティスバイオ インコーポレイティッド | 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法 |
| WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
| WO2022029051A1 (en) | 2020-08-03 | 2022-02-10 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| EP4192497A4 (en) | 2020-08-07 | 2024-08-21 | Othair Prothena Limited | MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| CN117751132A (zh) | 2020-08-07 | 2024-03-22 | 普罗塞纳生物科学有限公司 | 用于治疗阿尔兹海默氏病的tau疫苗 |
| CN116390937A (zh) | 2020-08-11 | 2023-07-04 | 治纳辅医药科技有限公司 | 一种包含il-12和抗cd20抗体的融合蛋白及其应用 |
| CN117098561A (zh) | 2020-08-28 | 2023-11-21 | 和铂医药美国股份有限公司 | Ccr8抗体及其应用 |
| CN115297889A (zh) | 2020-09-01 | 2022-11-04 | 荣昌生物制药(烟台)股份有限公司 | 抗c-Met抗体药物偶联物及其应用 |
| CA3192383A1 (en) | 2020-09-17 | 2022-03-24 | Robin Barbour | .beta.-amyloid vaccine for the treatment of alzheimer's disease |
| WO2022060488A1 (en) | 2020-09-18 | 2022-03-24 | Othair Prothena Limited | Multiepitope vaccine for the treatment of alzheimer's disease |
| WO2022058505A1 (en) | 2020-09-18 | 2022-03-24 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| IL300543A (en) | 2020-09-24 | 2023-04-01 | Hoffmann La Roche | Prevention or reduction of adverse effects associated with a bispecific T-cell antibody |
| WO2022072538A1 (en) | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| MX2023004054A (es) | 2020-10-07 | 2023-06-29 | Dren Bio Inc | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. |
| CA3198647A1 (en) | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| AR124562A1 (es) | 2020-10-28 | 2023-04-12 | Hoffmann La Roche | Receptores de unión al antígeno mejorada |
| JP7825633B2 (ja) | 2020-12-08 | 2026-03-06 | メモリアル スローン ケタリング キャンサー センター | ガレクチン－３に対する抗体及びその使用方法 |
| CN114656562B (zh) | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| MX2023007846A (es) | 2021-01-06 | 2023-07-07 | Hoffmann La Roche | Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20. |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| EP4284824A4 (en) | 2021-01-27 | 2025-03-12 | AbelZeta Inc. | CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 |
| MX2023008744A (es) | 2021-01-29 | 2023-10-02 | Illimis Therapeutics Inc | Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis. |
| KR20230153529A (ko) | 2021-02-19 | 2023-11-06 | 프리트 엠. 쇼드하리 | 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체 |
| BR112023018621A2 (pt) | 2021-03-15 | 2023-10-24 | Hoffmann La Roche | Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii |
| IL305886A (en) | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective release of drugs from internalized conjugates of biologically active compounds |
| CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| WO2022204282A1 (en) | 2021-03-24 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof |
| JP2024511465A (ja) | 2021-03-26 | 2024-03-13 | イナート・ファルマ・ソシエテ・アノニム | Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質 |
| EP4314050A4 (en) | 2021-04-02 | 2025-02-26 | The Board of Trustees of the Leland Stanford Junior University | BISPECIFIC MOLECULES AND RELATED COMPOSITIONS AND METHODS |
| MX2023012364A (es) | 2021-04-20 | 2023-11-01 | Seagen Inc | Modulacion de citotoxicidad celular dependiente de anticuerpos. |
| EP4326271A1 (en) | 2021-04-23 | 2024-02-28 | F. Hoffmann-La Roche AG | Prevention or mitigation of nk cell engaging agent-related adverse effects |
| EP4329804A4 (en) | 2021-04-26 | 2025-03-19 | TrueBinding, Inc. | Anti-gal3 antibody formulations and methods of use thereof |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022235622A2 (en) | 2021-05-04 | 2022-11-10 | Biocove Llc | Cd20 targeting fusion proteins and methods of use thereof |
| MX2023013264A (es) | 2021-05-12 | 2023-11-30 | Genentech Inc | Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes. |
| AU2022274319A1 (en) | 2021-05-12 | 2024-01-04 | Anaptysbio, Inc. | Antibody composition |
| EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| IL308795A (en) | 2021-05-28 | 2024-01-01 | Seagen Inc | Anthracycline antibody conjugates |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| US11987636B2 (en) | 2021-06-04 | 2024-05-21 | Xencor, Inc. | Dosing of a bispecific antibody that binds CD20 and CD3 |
| CN117897406A (zh) | 2021-06-08 | 2024-04-16 | 真和制药有限公司 | 抗gal3抗体及其用于胰岛素抵抗的方法 |
| US20250002601A1 (en) | 2021-06-09 | 2025-01-02 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| JP2024523838A (ja) | 2021-06-09 | 2024-07-02 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質 |
| MX2023014647A (es) | 2021-06-09 | 2024-01-31 | Innate Pharma | Proteinas de union a nkp46 multiespecificas. |
| CA3222934A1 (en) | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | Antibodies which bind human fibrin or fibrinogen yc domain and methods of use |
| CA3222880A1 (en) | 2021-06-18 | 2022-12-22 | Jeffrey Stavenhagen | Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use |
| CN117157098A (zh) | 2021-06-22 | 2023-12-01 | 荣昌生物制药(烟台)股份有限公司 | 一种药物组合及其用途 |
| EP4359442A4 (en) | 2021-06-25 | 2025-10-15 | Nanjing Immunophage Biotech Co Ltd | ANTI-CCR8 ANTIBODIES AND THEIR USES |
| KR20240040134A (ko) | 2021-07-09 | 2024-03-27 | 브라이트 피크 테라퓨틱스 아게 | 항체 접합체 및 이의 제조 |
| WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
| JP2024526764A (ja) | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| US20230197278A1 (en) | 2021-07-13 | 2023-06-22 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| EP4373859A1 (en) | 2021-07-22 | 2024-05-29 | F. Hoffmann-La Roche AG | Heterodimeric fc domain antibodies |
| US20240336697A1 (en) | 2021-08-07 | 2024-10-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
| WO2023019216A2 (en) | 2021-08-13 | 2023-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and treating ischemic eye disease |
| CN118591388A (zh) | 2021-09-29 | 2024-09-03 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| KR20240099224A9 (ko) | 2021-09-29 | 2025-12-10 | 모덱스 테라퓨틱스, 인크. | 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 이의 사용 방법 |
| CN115894701A (zh) | 2021-09-30 | 2023-04-04 | 上海君实生物医药科技股份有限公司 | 结合cd3的抗体及其用途 |
| AR127271A1 (es) | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |
| CN115746134A (zh) | 2021-10-15 | 2023-03-07 | 深圳市睿盟创新生物科技有限公司 | 半乳糖凝集素-3的免疫测定 |
| CA3236173A1 (en) | 2021-10-22 | 2023-04-27 | Centenaire Biosciences, Inc. | Antigen-binding protein comprising two fc domains and use thereof |
| WO2023077099A1 (en) | 2021-10-29 | 2023-05-04 | Zielbio, Inc. | Cancer specific plectin-1 specific antibodies and methods of use thereof |
| AU2022388722A1 (en) | 2021-11-09 | 2024-05-23 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| KR20240111753A (ko) | 2021-11-25 | 2024-07-17 | 에프. 호프만-라 로슈 아게 | 개선된 항원 결합 수용체 |
| TW202342105A (zh) | 2021-12-17 | 2023-11-01 | 大陸商北京加科思新藥研發有限公司 | 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途 |
| CN119930823A (zh) | 2021-12-23 | 2025-05-06 | 乐普创一生物科技（上海）有限公司 | 抗ccr8抗体及其应用 |
| EP4458861A1 (en) | 2021-12-29 | 2024-11-06 | Sichuan Huiyu Pharmaceutical Co., Ltd. | Antibody targeting cd3, multispecific antibody, and uses thereof |
| IL314119A (en) | 2022-01-12 | 2024-09-01 | Biomolecular Holdings Llc | Tetrahedral antibodies |
| WO2023137373A1 (en) | 2022-01-12 | 2023-07-20 | Biomolecular Holdings Llc | Tetrahedral antibodies |
| KR20240137640A (ko) | 2022-01-20 | 2024-09-20 | 상하이 준스 바이오사이언스 컴퍼니 리미티드 | 항-cd3 및 항-cd20 이중특이성 항체 및 이의 용도 |
| EP4466020A4 (en) | 2022-01-21 | 2026-04-15 | Lyvgen Biopharma Holdings Ltd | Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation |
| KR20230119859A (ko) | 2022-02-08 | 2023-08-16 | 연세대학교 산학협력단 | 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 |
| TW202400643A (zh) | 2022-02-28 | 2024-01-01 | 日商帝人製藥股份有限公司 | 神經退化性疾病之治療劑 |
| GB202203070D0 (en) | 2022-03-04 | 2022-04-20 | Iksuda Therapeutics Ltd | Anti-canag antibody conjugate |
| IL315508A (en) | 2022-03-17 | 2024-11-01 | Seagen Inc | Camptothecin conjugates |
| CN116789820A (zh) | 2022-03-18 | 2023-09-22 | 北京天诺健成医药科技有限公司 | 一种新型免疫调节剂的开发和应用 |
| WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| CN119562971A (zh) | 2022-03-25 | 2025-03-04 | 法国施维雅药厂 | 抗gal3抗体和组合物 |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| CN119301156A (zh) | 2022-04-04 | 2025-01-10 | 德伦生物公司 | 抗Dectin-1抗体和其使用方法 |
| US20250223364A1 (en) | 2022-04-04 | 2025-07-10 | Dren Bio, Inc. | Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof |
| IL316032A (en) | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| EP4508080A1 (en) | 2022-04-11 | 2025-02-19 | Astrazeneca AB | T cell binding proteins |
| CN119384432A (zh) | 2022-04-13 | 2025-01-28 | 基因泰克公司 | 治疗性蛋白质的药物组合物和使用方法 |
| CA3255366A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use |
| CA3255890A1 (en) | 2022-04-15 | 2023-10-19 | Mabsoft Therapeutics (Shanghai) Co., Ltd. | CONJUGATE COMPRISING A TOLL-TYPE RECEPTOR AGONIST |
| CN117003872A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 含有突变轻链可变区骨架的单链抗体片段 |
| IL316747A (en) | 2022-05-03 | 2025-01-01 | Xencor Inc | Lymphoma treatment methods |
| CA3252067A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory Antibody-Drug Conjugates |
| CN119233994A (zh) | 2022-05-25 | 2024-12-31 | 先天制药公司 | Nectin-4结合剂 |
| US20230416412A1 (en) | 2022-05-31 | 2023-12-28 | Hoffmann-La Roche Inc. | Prevention or mitigation of t-cell engaging agent-related adverse effects |
| WO2024001641A1 (zh) | 2022-07-01 | 2024-01-04 | 广东克冠达医药科技有限公司 | Cd101的抗体及其用途 |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| KR20250111753A (ko) | 2022-07-28 | 2025-07-22 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 자가면역질환 및 질병에 대한 바이오마커, 진단 방법, 치료법, 및 치료제 |
| AU2023320054A1 (en) | 2022-08-03 | 2025-02-06 | Regents Of The University Of Minnesota | Immunostimulatory anti-pd-l1-drug conjugates |
| WO2024036148A1 (en) | 2022-08-08 | 2024-02-15 | A2 Biotherapeutics, Inc. | Compositions and methods for treating blood cancers |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117051537A (zh) | 2023-07-03 | 2023-11-14 | 五邑大学 | 一种乙酰化葡甘聚糖静电纺丝膜及其制备方法与应用 |
-
2018
- 2018-07-24 EP EP18837376.5A patent/EP3658172A4/en active Pending
- 2018-07-24 CA CA3070446A patent/CA3070446A1/en active Pending
- 2018-07-24 AU AU2018308088A patent/AU2018308088B2/en not_active Expired - Fee Related
- 2018-07-24 US US16/633,530 patent/US12227567B2/en active Active
- 2018-07-24 CN CN201880061694.6A patent/CN111201030B/zh active Active
- 2018-07-24 WO PCT/US2018/043513 patent/WO2019023247A1/en not_active Ceased
- 2018-07-24 JP JP2020527838A patent/JP7368856B2/ja active Active
-
2023
- 2023-07-18 US US18/354,611 patent/US20240182564A1/en not_active Abandoned
- 2023-07-20 JP JP2023118382A patent/JP7789386B2/ja active Active
-
2025
- 2025-02-03 US US19/044,320 patent/US20250171539A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018308088A1 (en) | 2020-02-20 |
| WO2019023247A1 (en) | 2019-01-31 |
| JP7789386B2 (ja) | 2025-12-22 |
| CN111201030A (zh) | 2020-05-26 |
| JP2020529469A (ja) | 2020-10-08 |
| JP7368856B2 (ja) | 2023-10-25 |
| EP3658172A4 (en) | 2021-05-05 |
| US12227567B2 (en) | 2025-02-18 |
| US20250171539A1 (en) | 2025-05-29 |
| CN111201030B (zh) | 2024-11-01 |
| US20200223921A1 (en) | 2020-07-16 |
| US20240182564A1 (en) | 2024-06-06 |
| EP3658172A1 (en) | 2020-06-03 |
| JP2023145569A (ja) | 2023-10-11 |
| AU2018308088B2 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250171539A1 (en) | Treating cancer by blocking the interaction of tim-3 and its ligand | |
| CN107530423B (zh) | 用抗lap单克隆抗体治疗癌症 | |
| JP6586087B2 (ja) | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 | |
| KR20210030957A (ko) | 항-메소텔린 항체 | |
| HK1258249A1 (zh) | 用於测定icos表达的基因标志 | |
| JP2017506227A (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| JP6574257B2 (ja) | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 | |
| JP2024541680A (ja) | Ｃｃｒ８抗原結合ユニット及びその使用 | |
| WO2016133059A1 (ja) | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 | |
| US20210363255A1 (en) | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides | |
| JP2023546679A (ja) | がん治療における放射免疫療法とｃｄ４７遮断の併用 | |
| US20120070432A1 (en) | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine | |
| CN120647763A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| CA3151078A1 (en) | Anti-il-27 antibodies and uses thereof | |
| EP3914269B1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| KR20240058149A (ko) | Vista 항원-결합 분자를 사용한 암의 치료 및 예방 | |
| US20250296966A1 (en) | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor | |
| WO2023247660A1 (en) | Combination therapies | |
| CN119768423A (zh) | 组合疗法 | |
| JP2024528081A (ja) | 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ | |
| EP4509142A1 (en) | Fgfr4 as target in cancer treatment | |
| HK40098919A (zh) | 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法 | |
| HK40036031B (en) | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 | |
| HK40036031A (en) | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220916 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250515 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250523 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250630 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250630 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250722 |